Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo failure to follow SOPs, rethink broader GMP procedures draws FDA warning letter.

This article was originally published in The Tan Sheet

Executive Summary

PERRIGO FAILURE TO FOLLOW SOPs, RETHINK PROCEDURES DRAWS FDA WARNING LETTER sent to the Allegan, Mich.-based private label manufacturer on Sept. 23. The warning letter, from FDA's Detroit District Office, says there "appears to be a pattern of not following existing Standard Operating Procedures. Your systems have identified problems; however, the follow-up does not always determine the cause nor see resolution of the problem." Noting prior contact between FDA and the company wherein Perrigo proposed corrections to its Good Manufacturing Practices, the agency says "your representatives have been cautioned that all of the firm's Standard Operating Procedures should be evaluated, not only those cited."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel